Cyprotex launches new genomic analytical tool
CYPTROTEX, the Macclesfield-based drug testing company, has launched a new analytical tool which will help drug discovery firms to better understand their early-stage research.
The company has unveiled a new genomic ADME (absorption, distribution, metabolism, and excretion) service, which it said would provide drug researchers with “actionable data” on how genome structures respond to new compounds, particularly which enzymes play a role in the metabolism of their drugs.
This helps them to devise strategies to adjust doses depending on individual metabolism reactions and to improve patient care depending on their reaction to a compound.
It can also help to predict variability in pharmokinetic reactions to compounds, including variances in drug plasma levels between ethnic groups which has caused drug developers to abandon certain compounds.
Dr. Katya Tsaioun, Cyprotex’s chief scientific officer, said: “Many potentially valuable drugs are being discarded in early development.
“Cyprotex’s gADME™ service allows drug developers to understand the effect of genetic polymorphisms on drug toxicity and efficacy. This understanding will enable drug developers to identify appropriate dose adjustment strategies personalised for an individual’s genotype.
“This in turn can enable existing therapies to be repositioned, and successful development of drugs that would have heretofore been discarded.”
Dr Anthony Baxter, Cyprotex’s chief executive officer, said the launch “represents a significant milestone in Cyprotex’s scientific evolution”.
“In the past year, Cyprotex diversified into proprietary services spearheaded by our predictive toxicology technology CellCiphrTM and now gADME™ for genetic ADME. Last year, Cyprotex entered the in vitro toxicology market and we can now offer a large portfolio of predictive toxicology services.”
